Location: Animal Parasitic Diseases Laboratory
Project Number: 8042-32000-090-19-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Jul 1, 2013
End Date: Jun 30, 2014
The overall objective is to develop a protective vaccine against toxoplasmosis in animals and humans. At present there is no therapy to cure or prevent this disease.
The USDA is uniquely positioned to perform large-scale studies, survival studies not performed elsewhere, and studies with oocysts/sporozoites not performed elsewhere. The ability of immunotherapy to protect mice against oocyst induced disease will be tested in mice using oral inoculation with oocysts obtained from Type I, II III, and atypical strains in the Dubey Laboratory. Clinical, histologic, serologic, and immunologic parameters will be used to evaluate the efficacy of the vaccines for protection. Vaccination procedures will be optimized with different epitope preparations and appropriate adjuvant and delivery systems in HLA transgenic mice.